v3.26.3
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Income Statement [Abstract]        
Net revenue $ 862,684 $ 784,513 $ 2,381,400 $ 2,204,441
Cost of goods sold 528,566 510,539 1,392,661 1,388,323
Gross profit 334,118 273,974 988,739 816,118
Selling, general and administrative 139,645 137,815 427,227 380,369
Research and development 68,374 63,352 145,774 151,356
Intellectual property legal development expenses 2,193 2,437 5,822 6,221
Acquisition and integration costs 22,320 0 35,073 0
Restructuring and other charges 936 143 2,140 1,738
Change in fair value of contingent consideration (6,000) 0 (6,000) 0
Charges for property losses and associated expenses 5,369 0 5,369 0
Charges (credit) related to legal matters, net 6,497 0 15,248 (390)
Other operating income (631) (117) (8,870) (5,239)
Operating income 95,415 70,344 366,956 282,063
Other (expense) income:        
Interest expense, net (58,913) (62,814) (167,317) (184,854)
Foreign exchange (loss) gain, net (3,174) (3,431) (12,924) 9,072
Loss on refinancing (5,760) (31,365) (9,270) (31,365)
(Increase) decrease in tax receivable agreement liability (12,992) 20,808 (13,098) 5,701
Other income, net 481 1,235 1,876 3,357
Total other expense, net (80,358) (75,567) (200,733) (198,089)
Income (loss) before income taxes 15,057 (5,223) 166,223 83,974
Provision for (benefit from) income taxes 2,751 (23,355) 6,303 5,614
Net income 12,306 18,132 159,920 78,360
Less: Net income attributable to non-controlling interests (19,762) (15,763) (47,458) (41,379)
Net (loss) income attributable to Amneal Pharmaceuticals, Inc. before accretion of redeemable non-controlling interests (7,456) 2,369 112,462 36,981
Accretion of redeemable non-controlling interests (14,239) 0 (14,239) 0
Net (loss) income attributable to Amneal Pharmaceuticals, Inc. $ (21,695) $ 2,369 $ 98,223 $ 36,981
Net (loss) income per share attributable to Amneal Pharmaceuticals, Inc.’s Class A common stockholders:        
Basic (in dollars per share) $ (0.06) $ 0.01 $ 0.30 $ 0.12
Diluted (in dollars per share) $ (0.06) $ 0.01 $ 0.29 $ 0.11
Weighted-average common shares outstanding:        
Basic (in shares) 335,733 314,168 323,724 312,998
Diluted (in shares) 335,733 324,754 335,233 323,704